Identification
- Summary
Iron sucrose is an compound used as a source of iron in patients with iron deficiency anemia associated with chronic kidney disease (CKD).
- Brand Names
- Velphoro, Venofer
- Generic Name
- Iron sucrose
- DrugBank Accession Number
- DB09146
- Background
Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Iron sucrose (DB09146)
- Weight
- Average: 866.546
Monoisotopic: 866.764181 - Chemical Formula
- C12H29Fe5Na2O23
- Synonyms
- Ferric hydroxide sucrose complex
- Iron oxide saccharated
- Iron saccharate
- Iron sucrose
- Iron sucrose complex
- Iron sugar
- Iron(III) hydroxide sucrose complex
- Saccharated ferric oxide
- Saccharated iron
- Saccharated iron oxide
- Sucroferric oxyhydroxide
- External IDs
- XI 921
Pharmacology
- Indication
Iron sucrose is elemental iron as an injection. It replenishes body iron stores in patients with iron deficiency.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Hyperphosphataemia •••••••••••• ••••••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Significant increases in serum iron and serum ferritin and significant decreases in total iron binding capacity occurred four weeks from the initiation of iron sucrose treatment.
- Mechanism of action
Following intravenous administration, iron sucrose is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron is then incorporated into hemoglobin as the cells mature into red blood cells.
- Absorption
The intravensously administered iron sucrose injection would result rapidly in high serum iron levels. Maximum measured levels occured after 10 min of injection with an average of 30.00 mg/l.
- Volume of distribution
Vd is 7.3 L
- Protein binding
It binds with transferrin.
- Metabolism
Following IV administration, dissociated into iron and sucrose by the reticuloendothelial system.
- Route of elimination
Renal elimination of iron contributed very little to the total elimination (in average less than 5%). While, renal elimination of sucrose accounts for 68-75% of the administered dose after 4 and 24 hours respectively.
- Half-life
6 hours.
- Clearance
Total body clearance is 20.5 ml/min.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Hypersensitivity reactions, including anaphylactic shock, loss of consciousness, collapse, hypotension, dyspnea, and seizure. Monitor iron toxicity through the periodic evaluation of lab works which monitor the body concentration of iron. Lab monitoring of the following parameters: transferrin saturation, serum ferritin concentrations, hemoglobin, and hematocrit could be helpful to avoid iron overload. Severe allergic symptoms include: rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); burning or pain at the injection site; burning, numbness, or tingling; chest pain; fainting; loss of consciousness; severe or persistent dizziness, headache, or light-headedness; seizures; shortness of breath; swelling of the hands, ankles, or feet.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetylsalicylic acid The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Iron sucrose. Alendronic acid Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Almasilate Almasilate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Take with food. Take with meals to maximize phosphate binding capacity and reduce phosphate absorption.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Iron unknown E1UOL152H7 7439-89-6 XEEYBQQBJWHFJM-UHFFFAOYSA-N Ferric cation ionic 91O4LML611 20074-52-6 VTLYFUHAOXGGBS-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Colliron IV / Encifer / Fe-back / Feojectin / Ferijet / Ferosoft S / Ferplex SS / Ferrivenin
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Velphoro Tablet, chewable 500 mg/1 Oral Fresenius Medical Care North America 2013-11-27 Not applicable US 
Velphoro Tablet 125 mg Oral Vifor Fresenius Medical Care Renal Pharma France 2020-12-16 Not applicable EU 
Velphoro Tablet, chewable 500 mg Oral Vifor Fresenius Medical Care Renal Pharma France 2020-12-16 Not applicable EU Velphoro Tablet, chewable 500 mg Oral Vifor Fresenius Medical Care Renal Pharma Ltd 2019-11-20 Not applicable Canada 
Velphoro Tablet, chewable 500 mg Oral Vifor Fresenius Medical Care Renal Pharma France 2020-12-16 Not applicable EU - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image PMS-iron Sucrose Solution 20 mg / mL Intravenous Pharmascience Inc 2021-01-12 Not applicable Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Myferon 150 Capsule 150 mg/1 Oral Martin Ekwealor Pharmaceuticals, Inc. 1996-12-01 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bal-Care DHA Iron sucrose (1.35 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2850 [iU]/1) + Calcium carbonate (219 mg/1) + Cholecalciferol (840 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (.012 mg/1) + DL-alpha tocopheryl acetate (3 mg/1) + Folic acid (1 mg/1) + Iodine (.223 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (430 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Sodium feredetate (25.65 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1) Kit Oral Pru Gen Pharmaceuticals 2012-05-01 Not applicable US Bal-Care DHA Essential Iron sucrose (1.35 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2850 [iU]/1) + Calcium carbonate (219 mg/1) + Cholecalciferol (840 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (.012 mg/1) + DL-alpha tocopheryl acetate (3 mg/1) + Folic acid (1 mg/1) + Iodine (.223 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (374 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Sodium feredetate (25.65 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1) Kit Oral Pru Gen Pharmaceuticals 2012-05-01 Not applicable US Choice OB DHA Iron sucrose (29 mg/1) + Ascorbic acid (60 mg/1) + Beta carotene (1700 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cyanocobalamin (5 ug/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Doconexent (250 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (15 ug/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (15 mg/1) Kit Oral Acella Pharmaceuticals, LLC 2013-05-17 2015-07-31 US 
DEMROSE 100 MG/5 ML IV ENJEKSIYON VE INFUZYON ICIN KONSANTRE COZELTI ICEREN AMPUL, 5 ADET Iron sucrose (100 mg/5ml) Solution Intravenous PHARMADA İLAÇ SAN. VE TİC. A.Ş. 2018-07-31 2024-01-23 Turkey 
HemeNatal OB Iron sucrose (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Sodium selenate (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (4.5 mg/1) + alpha-Tocopherol succinate (10 [iU]/1) Tablet Oral Wh Nutritionals, Llc 2012-03-08 2018-06-30 US
Categories
- ATC Codes
- B03AB02 — Saccharated iron oxide
- B03AB — Iron trivalent, oral preparations
- B03A — IRON PREPARATIONS
- B03 — ANTIANEMIC PREPARATIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Acids, Acyclic
- Carbohydrates
- Disaccharides
- Drugs for Treatment of Hyperkalemia and Hyperphosphatemia
- Ferric Compounds
- Hydroxy Acids
- Iron Compounds
- Iron Preparations
- Iron Trivalent, Oral Preparations
- Oligosaccharides
- Organometallic Compounds
- Pharmaceutical Preparations
- Phosphate-removing Agents
- Polysaccharides
- Sugar Acids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbohydrates and carbohydrate conjugates
- Direct Parent
- O-glycosyl compounds
- Alternative Parents
- Disaccharides / C-glycosyl compounds / Ketals / Oxanes / Tetrahydrofurans / Secondary alcohols / Polyols / Oxacyclic compounds / Organic transition metal salts / Primary alcohols show 5 more
- Substituents
- Acetal / Alcohol / Aliphatic heteromonocyclic compound / C-glycosyl compound / Disaccharide / Hydrocarbon derivative / Ketal / O-glycosyl compound / Organic alkali metal salt / Organic hydroxide show 12 more
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FZ7NYF5N8L
- CAS number
- 8047-67-4
- InChI Key
- FWZTTZUKDVJDCM-CEJAUHOTSA-M
- InChI
- InChI=1S/C12H22O11.5Fe.2Na.4H2O.8O/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;;;;;;;;;;;;;;;;;;;/h4-11,13-20H,1-3H2;;;;;;;;4*1H2;;;;;;;;/q;5*+3;2*+1;;;;;8*-2/p-1/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;/m1.................../s1
- IUPAC Name
- pentairon(3+) ion disodium (2R,3R,4S,5S,6R)-2-{[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol trihydrate hydroxide octaoxidandiide
- SMILES
- O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
References
- General References
- External Links
- PubChem Compound
- 91663255
- PubChem Substance
- 310265059
- ChemSpider
- 32699616
- 1484283
- ChEMBL
- CHEMBL1200823
- Wikipedia
- Iron_sucrose
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Basic Science Other and unspecified effects of high altitude 1 4 Completed Diagnostic Anemia in Chronic Renal Disease 1 4 Completed Other Variola Major (Smallpox) 1 4 Completed Supportive Care Anemia of Chronic Kidney Disease 1 4 Completed Treatment Anemia 3
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit Oral Injection, solution, concentrate Intravenous 100 mg/5ml Solution Intravenous 100 mg/5ml Injection Intravenous Solution Parenteral 20 mg/1ml Injection, solution Intravenous 100 mg/5ml Solution Intravenous 2000 mg/5ml Injection, solution Parenteral 100 mg/5ml Solution, concentrate Parenteral Solution Intravenous 20 mg Solution Intravenous 1754.000 mg Injection Intravenous 400 MG Tablet Oral Solution Intravenous 100 mg Injection, solution, concentrate Intravenous 2700 mg Capsule Oral Capsule Oral 150 mg/1 Solution Oral Solution Intramuscular 100 mg Tablet, coated Oral Suspension / drops Oral Capsule, liquid filled Oral Capsule, liquid filled; kit; tablet, coated Oral Injection Intravenous 100 MG/5ML Injection Intravenous 20 mg/ml Capsule Oral Powder, for suspension Oral 125 MG Tablet Oral 125 mg Tablet Oral 2500.00 mg Tablet Oral 500 MG Tablet, chewable Oral 500 mg/1 Tablet, chewable Oral 500 mg Solution Oral 100 mg/5mL Injection Intravenous 75 mg/3.75mL Injection, solution Intravenous Injection, solution Intravenous 20 mg/1mL Injection, solution Intravenous 20 MG/ML Injection, solution Parenteral 20 mg/1ml Solution Intravenous 20 mg / mL Injection, solution, concentrate Intravenous Injection, solution, concentrate Intravenous 20 mg/ml Solution Intravenous Solution Parenteral 2700.0 mg Tablet, film coated Oral Capsule, gelatin coated Oral - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6174442 No 2001-01-16 2016-12-19 US US9561251 Yes 2017-02-07 2030-07-23 US US10624855 Yes 2020-04-21 2035-05-26 US US10682376 Yes 2020-06-16 2029-05-13 US US10695367 Yes 2020-06-30 2029-05-13 US US10925896 Yes 2021-02-23 2029-05-13 US US10925897 Yes 2021-02-23 2029-05-13 US US10933090 Yes 2021-03-02 2029-05-13 US US11013761 Yes 2021-05-25 2029-05-13 US US11013762 Yes 2021-05-25 2029-05-13 US US11234938 Yes 2015-05-26 2035-05-26 US US11446252 Yes 2015-05-26 2035-05-26 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 9.52 mg/mL ALOGPS logP 1.99 ALOGPS logP -4.5 Chemaxon logS -1.8 ALOGPS pKa (Strongest Acidic) 11.84 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 11 Chemaxon Hydrogen Donor Count 8 Chemaxon Polar Surface Area 189.53 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 68.77 m3·mol-1 Chemaxon Polarizability 30.97 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 01, 2015 16:49 / Updated at February 20, 2024 23:54